Basrah - College of Pharmacy Media:

The College of Pharmacy at the University of Basrah organized a seminar titled "Migraine," in a lecture presented by Dr. Abrar Salman Abdul Razzaq.

The seminar included an explanation of migraine, which is a neurological disease that affects women more than men by a ratio of (3:1) and is considered a hereditary disease. Among its most important symptoms are unilateral headache, vomiting, nausea, sensitivity to light and sound, and constipation.

The seminar explained that there are many drugs used to treat migraines and others to prevent them. A new drug for migraine prevention was discovered, with the scientific name Erenumab and the trade name Aimovig. This drug works by blocking Calcitonin Gene-Related Peptide (CGRP) receptors and is available in two concentrations (140 mg and 70 mg). It was approved by the US Food and Drug Administration (FDA) in 2018.

The seminar clarified the method of using this treatment by administering it subcutaneously once a month by the patient themselves. What distinguishes this treatment is that it does not interact with other drugs because it is not metabolized in the liver. Additionally, it can be used by patients with liver, kidney, and heart diseases. Its side effects are limited to abdominal cramps, muscle spasms, constipation, and some local effects at the injection site.

❧ ☙